ABSTRACT
The angiopoietin (Ang) family of growth factors includes Ang1, Ang2, Ang3, and Ang4, all of which bind to the endothelial receptor tyrosine kinase Tie2. Ang3 (mouse) and Ang4 (human) are interspecies orthologs. In experiments with human endothelial cell lines, Ang3 was identified as an antagonist of Tie2 and Ang4 was identified as an agonist of Tie2. However, the biological roles of Ang3 and Ang4 are unknown. We examined the biological effect of recombinant Ang3 and Ang4 proteins in primary cultured endothelial cells and in vivo in mice. Recombinant Ang3 and Ang4 formed disulfide-linked dimers. Ang4 (400 ng/mL) markedly increased Tie2 and Akt phosphorylation in primary cultured HUVECs whereas Ang3 (400 ng/mL) did not produce significant changes. Accordingly, Ang4, but not Ang3, induced survival and migration in primary cultured HUVECs. Unexpectedly, intravenously administered Ang3 (30 microg) was more potent than Ang4 (30 microg) in phosphorylating the Tie2 receptor in lung tissue from mice in vivo. Accordingly, Ang3 was more potent than Ang4 in phosphorylating Akt in primary cultured mouse lung microvascular endothelial cells. Ang3 and Ang4 both produced potent corneal angiogenesis extending from the limbus across the mouse cornea in vivo. Thus, Ang3 and Ang4 are agonists of Tie2, but mouse Ang3 has strong activity only on endothelial cells of its own species.
Subject(s)
Angiopoietins/physiology , Corneal Neovascularization/etiology , Endothelial Cells/metabolism , Endothelium, Vascular/metabolism , Receptor, TIE-2/agonists , Ribonucleases/physiology , Angiopoietin-1/chemistry , Angiopoietin-1/genetics , Angiopoietin-1/pharmacology , Angiopoietin-1/physiology , Angiopoietin-2/chemistry , Angiopoietin-2/genetics , Angiopoietin-2/pharmacology , Angiopoietin-2/physiology , Angiopoietin-Like Protein 1 , Angiopoietin-Like Protein 4 , Angiopoietin-like Proteins , Angiopoietins/chemistry , Angiopoietins/genetics , Angiopoietins/pharmacology , Animals , Apoptosis/drug effects , Blood Proteins/genetics , Blood Proteins/physiology , Capillaries/cytology , Cell Movement/drug effects , Cells, Cultured/drug effects , Cells, Cultured/metabolism , Dimerization , Endothelial Cells/drug effects , Endothelium, Vascular/cytology , Humans , Intercellular Signaling Peptides and Proteins/genetics , Intercellular Signaling Peptides and Proteins/pharmacology , Intercellular Signaling Peptides and Proteins/physiology , Lung/blood supply , Male , Mice , Phosphorylation/drug effects , Protein Processing, Post-Translational/drug effects , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt , Recombinant Fusion Proteins/physiology , Ribonucleases/chemistry , Ribonucleases/genetics , Ribonucleases/pharmacology , Species Specificity , Transfection , Umbilical VeinsABSTRACT
Interaction between ephrinB2 and EphB4 in endothelial cells at the arterial-venous capillary interface is critical for proper embryonic capillary morphogenesis. However, the intracellular downstream signaling of ephrinB2-EphB in vascular endothelial cells is unknown. This study examined the effect of ephrinB2-induced activation of EphB kinases on vascular endothelial growth factor (VEGF)- and angiopoietin-1 (Ang1)-induced Ras/mitogen-activated protein kinase (MAPK) signaling cascades in human umbilical vein endothelial cells (HUVECs). Reverse transcriptase-polymer chain reaction results showed that HUVECs expressed three kinds of EphB kinases known to bind to ephrinB2: EphB2, EphB3, and EphB4. EphrinB2 not only increased the phosphorylation of EphB2 and EphB4 in a time-dependent manner but also increased recruitment of p120-Ras-GTPase-activating protein (p120-RasGAP) to EphB2 and EphB4. Accordingly, ephrinB2 inhibited VEGF- and Ang1-induced Ras-MAPK activities, whereas ephrinB2 did not alter VEGF-induced Flk phosphorylation or Ang1-induced Tie2 phosphorylation. Furthermore, ephrinB2 suppressed VEGF- and Ang1-induced proliferation and/or migration, which are mediated mainly through Ras/MAPK signaling cascades. From these results, we propose that ephrinB2-EphB, signaling through Ras/MAPK cascade, may be critical for proper morphogenesis of capillary endothelium through the arrest of endothelial cell proliferation and migration at the arterial-venous interface.
Subject(s)
Endothelial Growth Factors/antagonists & inhibitors , Endothelium, Vascular/metabolism , Lymphokines/antagonists & inhibitors , Membrane Glycoproteins/antagonists & inhibitors , Membrane Proteins/pharmacology , Mitogen-Activated Protein Kinases/metabolism , Proto-Oncogene Proteins p21(ras)/metabolism , Angiopoietin-1 , Cell Division/drug effects , Cell Movement/drug effects , Cells, Cultured , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiology , Ephrin-B2 , Humans , Ligands , MAP Kinase Signaling System/drug effects , Models, Biological , Phosphorylation , Receptor Protein-Tyrosine Kinases/metabolism , Receptor, EphB2 , Receptor, EphB4 , Receptors, Eph Family , Umbilical Veins/cytology , Umbilical Veins/physiology , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors , p120 GTPase Activating Protein/metabolismABSTRACT
Normally, tissue factor (TF) is not expressed on the surface of endothelial cells, but its expression can be induced by vascular endothelial growth factor (VEGF) and tumor necrosis factor (TNF)-a. However, the signaling pathway(s) affecting this induction is unknown. Using human umbilical vein endothelial cells, we found that inhibitors of guanine-cytosine-rich DNA binding protein and nuclear factor (NF)-kB suppressed VEGF- and TNF-a-induced expression and activity of TF. However, unexpectedly, phosphatidylinositol (PI) 3'-kinase inhibitor enhanced the VEGF- and TNF-a-induced expression and activity of TF. Angiopoietin-1 (Ang1), a strong activator of intracellular PI 3'-kinase/Akt, inhibited the induction of TF by VEGF and TNF-a, whereas Ang1 itself did not produce any significant effect on TF. Selective activation (or inactivation) of PI 3'-kinase/Akt by using adenoviral transfer reduced (or enhanced) TNF-a-induced expression of TF mRNA and protein, regardless of Ang1 treatment. From these results, we conclude that Ang1 inhibits the up-regulation of TF expression, possibly through activation of PI 3'-kinase/Akt in endothelial cells. Ang1 may be useful as an inhibitor of VEGF- and TNF-a-induced coagulation, inflammation, and cancer progression.
